Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. (Q37130325)
Jump to navigation
Jump to search
scientific article published on 19 August 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. |
scientific article published on 19 August 2011 |
Statements
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design (English)
Geoffrey R Oxnard
Vincent A Miller
Gregory J Riely
19 August 2011